Wikisage, the free encyclopedia of the second generation, is digital heritage
Eslicarbazepine: Difference between revisions
Jump to navigation
Jump to search
(→Pharmacy and chemistry: rfz) |
|||
Line 4: | Line 4: | ||
Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the [[European Medicines Agency|EMA]] (Zerebix TM) and recently by the American [[FDA]]<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480532/pdf/10.1177_1756285615589711.pdf A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures]</ref> | Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the [[European Medicines Agency|EMA]] (Zerebix TM) and recently by the American [[FDA]]<ref>[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480532/pdf/10.1177_1756285615589711.pdf A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures]</ref> | ||
Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to carbazepine; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)<ref>https://www.dovepress.com/clinical-utility-of-eslicarbazepine-current-evidence-peer-reviewed-article-DDDT</ref> | Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to carbazepine; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)<ref>https://www.dovepress.com/clinical-utility-of-eslicarbazepine-current-evidence-peer-reviewed-article-DDDT</ref> | ||
==Pharmacology== | |||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448990/ Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action] | |||
<references/> | <references/> |
Revision as of 03:08, 20 September 2015
is an AED. Adjunctive eslicarbazepine led to seizure reduction in two patients with severe myoclonic epilepsy of infancy[1]
Pharmacy and chemistry
Eslicarbamazepine acetate is an once-daily antiepileptic that was approved in 2009 by the EMA (Zerebix TM) and recently by the American FDA[2] Eslicarbamazepine is the prodrug of S-licarbazepine, both oxcarbazapine and eslicarbazepine metabolize same, different to carbazepine; the latter metabolizes to CBZ 10,11-epoxide (Hainzl et al, 2001)[3]
Pharmacology
- ↑ Severe myoclonic epilepsy of infancy: Seizure reduction during adjunctive eslicarbazepine in two cases
- ↑ A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures
- ↑ https://www.dovepress.com/clinical-utility-of-eslicarbazepine-current-evidence-peer-reviewed-article-DDDT